Editorial Commentary: Can a Reduced-Dose Prophylaxis Schedule Provide Adequate Coverage Against Respiratory Syncytial Virus Infection?

Affiliations

¹ Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts.
² Division of Epidemiology 1, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.

Editorial

Catherine A Panozzo et al. Clin Infect Dis. 2015.

. 2015 Aug 15;61(4):515-6.

doi: 10.1093/cid/civ336. Epub 2015 Apr 22.

¹ Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts.
² Division of Epidemiology 1, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.

No abstract available

Keywords: RSV; clinical guideline; palivizumab; respiratory syncytial virus; seasonality.

Comment on

Reduced-Dose Schedule of Prophylaxis Based on Local Data Provides Near-Optimal Protection Against Respiratory Syncytial Virus.
Weinberger DM, Warren JL, Steiner CA, Charu V, Viboud C, Pitzer VE. Weinberger DM, et al. Clin Infect Dis. 2015 Aug 15;61(4):506-14. doi: 10.1093/cid/civ331. Epub 2015 Apr 22. Clin Infect Dis. 2015. PMID: 25904370 Free PMC article.